AI-Powered Early Detection of Cardiovascular Disease

Starting with HFpEF and cardiac amyloidosis, we are helping clinicians uncover hidden disease signals in two severely undiagnosed conditions.

WHAT WE DO

Using AI to surface hidden disease signals

Cardiovascular diseaase often develops silently. Even with routine echoacardiography, subtle disease patterns can be difficult to recognize,a delaying further assessment and appropriate care.

Ultromics develops AI that helps clinicians surface clinically relevant findings that may otherwise go unrecognized, supporting more informed diagnostic pathways from one of the world's most widely used cardiac imaging tests.

Millions of people live with cardiovascular disease that can remain unrecognized for years. Conditions such as heart failure with preserved ejection fraction (HFpEF) and cardiac amyloidosis often present with subtle findings that can be difficult to detect.

We believe artificial intelligence can help improve that.

Beginning with HFpEF and cardiac amyloidosis, Ultromics provides AI that supports clinicians in identifying these complex conditions through routine echocardiography, helping inform diagnostic pathways and treatment decisions.

It’s happening right now.

This isn’t future-facing AI.
It is already live inside real clinical workflows.

Today, leading hospitals already use Ultromics to support heart failure assessment and cardiac amyloidosis screening during in assessments and reporting. Our AI is designed to integrate seamlessly into existing workflows, providing additional clinical insight without disrupting how clinicians work.

Request a demo

Explore case studies

OUR JOURNEY

Built on scientific rigor. Proven in clinical practice.

Our journey began at the University of Oxford, where sonographer Ross Upton, M.D., saw the potential of AI to address longstanding challenges in echocardiography.

Echocardiography is one of the most important tools in cardiovascular care. But interpretation can be subjective and time consuming, and in complex disease, the signals can be subtle. As a result, clinically important findings can go unrecognized.

Working alongside Professor Paul Leeson, Ross developed an AI approach designed to move beyond automating measurements and instead help identify disease directly from routine echocardiography. That research became the foundation of EchoGo and the beginning of Ultromics.

Nearly a decade later, Ultromics is live in leading U.S. hospitals, with three FDA clearances, two breakthrough device designations, published clinical evidence, established reimbursement pathways, and support from world-renowned partners including Mayo Clinic, Pfizer, Johnson & Johnson Innovative Medicine, and FNIH.

See clinical validation

500,000+

Real-world scans analyzed

10+ yrs

outcome data powering model development and validation

FDA clearances, including 2 FDA device breakthrough designations.

WHY ULTROMICS

Built on science.
Proven in practice.

From pioneering research at the University of Oxford to real-world clinical deployment, Ultromics is built on evidence, validated through research, and working with leading organizations to advance heart failure detection.

10+ YEARS OF RESEARCH

Built on scientific rigor

PEER REVIEWED

Clinically evaluated

FDA CLEARED

FDA cleared
and recognized innovation

2025 ASE GUIDELINES

Cited in clinical guidelines

CMS • CPT 0932T

Incremental reimbursement

MAYO CLINIC

Developed with cardiovascular experts

530,000+ REAL WORLD CASES

Proven in practice

AHA • FNIH • PFIZER

Working with leading partners

ECHO FIRST

Seamless Integration with echo workflows

AI Assessment Lab

Independent analysis projects show how AI could help health systems identify more patients earlier, improve access to care, and reduce the burden of undiagnosed cardiovascular disease.

View report

Strategic Investment from the American Heart Association's Go Red for Women Venture Fund

The American Heart Association's Go Red for Women Venture Fund made a strategic investment in Ultromics, supporting our mission to improve earlier identification of heart disease through AI.

Learn more

$55M Series C to scale clinical adoption

Strategic investors include L&G, GV (Google Ventures), Lightrock, Oxford Science Enterprises and Blue Venture Fund.

Learn more

Ross Upton, PhD

Founder & CEO

From a PhD at the University of Oxford to building one of the first FDA-cleared AI platforms for echocardiography, Ross has spent more than a decade translating cardiovascular research into clinical practice.

Paul Leeson, MD

Professor of Cardiovascular Medicine, University of Oxford

Academic collaborator from the earliest stages of the technology, helping develop AI methods to improve cardiovascular diagnosis from routine echocardiography.

Patricia Pellikka, MD

Vice chair of the department of cardiovascular medicine at Mayo Clinic

International leader in echocardiography whose clinical expertise helped shape the development and validation of EchoGo. Co-author of foundational clinical research behind the platform.